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Pancreatic neuroendocrine tumors (PanNET) account for 1-3% of all pancreatic 
cancers and are frequently diagnosed at a stage at which distant metastases are evident1. 
Although recent studies2 have identified driver genes implicated in PanNET development, 
the molecular events underlying tumor evolution and metastases remain unknown. To 
gain insight into these processes, we undertook whole-exome sequencing of 12 
asynchronously-collected tumor samples from a single PanNET patient over a ~13-year 
window. 
The patient, a 54-year-old male, presented with a ~25×24mm mass in the 
pancreatic tail and a metastatic lesion in the right lobe of the liver, which was initially 
misdiagnosed as pancreatic ductal adenocarcinoma. Over the disease course, the 
patient underwent six surgeries and multiple rounds of chemotherapy (Figure 1a). 
Details of clinical treatment together with supplementary methods, notes, figures, and 
tables are provided online (http://www.igenetics.org.cn/project/PanNET/). The 
pathological diagnosis was revised 9-years after the initial surgery to that of a well-
differentiated PanNET (G2, Ki67=3%, Figure 1b; online Figure S1a). 
The primary tumor revealed a very high mutation burden (84/MB), a sign of 
hypermutability3 (online Figure S1b) and single base substitution (SBS) signature 
analysis supported defective DNA repair processes (online Figure S1c). Strikingly, this 
hypermutation phenotype was not observed in any of the synchronous or metachronous 
metastases. Somatic variants in known PanNET driver genes including MEN1 
(p.Tyr77fs*42, NP_570716), TSC2 (p.His1860Cysfs*58, XP_005255584.1) and DAXX 
(p.Pro284Arg, NP_001356132.1) were observed in all tumor samples (Figure 1c), 
consistent with their established roles in tumorigenesis. The patient was also noted to 
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harbor a rare germline missense TSC2 variant (p.Arg1369Gln, NP_000539), associated 
with aberrant mTOR signaling in vitro (online Figure S1d-e). Notably, the patient 
received the mTOR inhibitor everolimus following the last surgery, associated with 
disease stability. 
Analysis of the clonal and subclonal architecture4 indicated that the majority of 
metastatic subclones could be traced back to the primary tumor (Figure 1d). However, 
the low mutation burden observed in each of the metastases indicated that the 
acquisition of metastatic potential and cancer progression was not a late-event 
dependent on the hypermutation observed in the primary tumor (as described in other 
cancers4), but arose independent of this at an earlier timepoint. Furthermore, somatic 
trunk variants in metastasis-associated driver genes (i.e., TSC2 and DAXX), as well in 
metastasis-specific variants in extracellular matrix genes further support such a model. 
Subsequent phylogenetic analysis revealed that subclones in the primary tumor (Figure 
1e) had both linear and branching seeding patterns. Metastatic spread was dependent 
on two likely processes; metastatic subclones arising directly from the primary tumor 
and persisting at clinically occult sites over long periods prior to detection (e.g., dark-
blue subclone); and polyclonal seeding events with subsequent metastasis-to-
metastasis spread as reported for other cancer types (e.g., purple subclone) (Figure 
1f)4,5.  
In summary, this study highlights the utility of temporal and spatial genomic 
sampling of multiple tumors from a single patient to investigate the genetic factors 
influencing PanNET disease course, and provides useful insights into tumor initiation, 
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the potential timing of metastatic seeding, and subsequent metastatic trajectory, which 
together have potentially important therapeutic implications. 
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Figure 1 – A PanNET patient with multiple metastatic deposits. 
(a) Clinical timeline of the patient’s tumor development and disease course. The 
timeline axis at the top and bottom records the relative timing of the tumor imaging 
(CT/MRI), surgeries, and therapeutic interventions (online Table S1-S3). The vertical 
axis provides a scale for the tumor volumes (online Table S2). The primary tumor (A) is 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































L) in blue. The lymph node LN13 in represented in grey as it is still in situ within the 
patient. The colored bars at the bottom of the panel represent different drugs included in 
cycles of chemotherapy, with the width corresponding to the therapeutic intervals each 
combination was used. These sequential rounds of post-operative adjuvant 
chemotherapy were administered based on the initial misdiagnosis of pancreatic ductal 
adenocarcinoma. 
(b) IHC staining for Ki67 in tumor samples (online Table S4). A Ki67 index of 3% was 
observed in the primary tumor whilst rates of 2%, 2%, 10%, and 8% were observed in 
the liver metastases (tumors B, C, D, and E), respectively. No correlation was observed 
between Ki67 index and tumor mutation burden (p=0.62). 
(c) Distribution of non-silent somatic mutations shared between at least two of the tumor 
samples, i.e., trunk and branch mutations. 
(d) Clonal and subclonal architecture of the tumor samples inferred by the distribution of 
non-silent mutations and selected copy number variants (CNVs) shared between 
samples (online notes). Tumor clones are represented by ovals, with the likely clonal 
and subclonal fractions in each sample indicated. Each row represents a sample, with 
the ovals in the column presented in nested format. The area of each oval represents 
the estimated proportion of the corresponding subclones. Oval plots are divided into 
three types: trunk, branch and leaf. 
(e) The inferred phylogenetic tree. Branch length is proportional to the number of 
substitutions. Branches are annotated with sample(s) (i.e. A-L) in which they are 
present, and with potential driver events assigned to that subclone. Genes represented 
 9 
in bold are experimentally validated metastases-related genes from the human cancer 
metastasis database. Amp, amplification; Del, deletion.  
(f) Inferred pattern of metastatic seeding events is represented with color-coded arrows. 
In the left-hand panel, the solid arrows indicate the inferred spread of metastatic clones 
direct from the primary tumor. The detection of subclones represented by the purple and 
light blue arrows at tumor C indicate possible polyclonal seeding. Our analysis suggests 
a potential mechanism represented in the middle panel, in which the purple clone 
identified in tumor C subsequently undergoes metastasis-to-metastasis seeding (i.e. 
from tumor C to the remaining metastatic locations, represented by dotted arrows), 
although it is also possible that the subsequent detection of the purple clone in all 
samples except sample B, may indicate direct spread from the primary tumor (i.e. tumor 
clones persisting at these sites over long periods prior to detection) (see online notes for 
additional details). In the right-hand panel, the double-headed arrows indicate instances 
in which seeding could be in either direction.  
